| __timestamp | Eli Lilly and Company | Taro Pharmaceutical Industries Ltd. |
|---|---|---|
| Wednesday, January 1, 2014 | 4932500000 | 179279000 |
| Thursday, January 1, 2015 | 5037200000 | 186359000 |
| Friday, January 1, 2016 | 5654900000 | 171785000 |
| Sunday, January 1, 2017 | 6070200000 | 208136000 |
| Monday, January 1, 2018 | 4681700000 | 198405000 |
| Tuesday, January 1, 2019 | 4721200000 | 224169000 |
| Wednesday, January 1, 2020 | 5483300000 | 245044000 |
| Friday, January 1, 2021 | 7312800000 | 252314000 |
| Saturday, January 1, 2022 | 6629800000 | 268225000 |
| Sunday, January 1, 2023 | 7082200000 | 304629000 |
| Monday, January 1, 2024 | 8418299999 | 324203000 |
Unleashing the power of data
In the competitive world of pharmaceuticals, cost efficiency is a critical factor for success. This analysis delves into the cost of revenue trends for Eli Lilly and Company and Taro Pharmaceutical Industries Ltd. over the past decade. From 2014 to 2023, Eli Lilly's cost of revenue has shown a significant upward trend, peaking in 2021 with a 48% increase from 2014. In contrast, Taro's cost of revenue has grown more modestly, with a 70% increase over the same period, reflecting a steady but less volatile growth pattern.
Eli Lilly's cost efficiency appears to fluctuate, with notable dips in 2018 and 2019, while Taro maintains a more consistent trajectory. This data provides valuable insights into the operational strategies of these pharmaceutical giants, highlighting Eli Lilly's aggressive growth and Taro's steady approach. Missing data for 2024 suggests ongoing developments in this dynamic industry.
Eli Lilly and Company vs Bristol-Myers Squibb Company: Efficiency in Cost of Revenue Explored
Cost of Revenue Comparison: Eli Lilly and Company vs Neurocrine Biosciences, Inc.
Cost of Revenue: Key Insights for Eli Lilly and Company and Grifols, S.A.
Cost of Revenue Trends: Eli Lilly and Company vs CRISPR Therapeutics AG
Cost Insights: Breaking Down Eli Lilly and Company and Travere Therapeutics, Inc.'s Expenses
Eli Lilly and Company vs BioCryst Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Who Generates Higher Gross Profit? Eli Lilly and Company or Taro Pharmaceutical Industries Ltd.
Analyzing Cost of Revenue: Eli Lilly and Company and Xencor, Inc.
Comparing Cost of Revenue Efficiency: Novo Nordisk A/S vs Taro Pharmaceutical Industries Ltd.
Halozyme Therapeutics, Inc. vs Taro Pharmaceutical Industries Ltd.: Efficiency in Cost of Revenue Explored
Cost of Revenue: Key Insights for Vericel Corporation and Taro Pharmaceutical Industries Ltd.
Comparing Cost of Revenue Efficiency: Ligand Pharmaceuticals Incorporated vs Taro Pharmaceutical Industries Ltd.